Where Are We on the Path to Elimination of Chronic Hepatitis C?

Slides:



Advertisements
Similar presentations
Hepatitis C In Alaska’s Department of Corrections
Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Edo Agustian Indonesian Drug Users Network Experiencing HCV Infection – the treatment, the reality and the possibilities for Cure.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
The changing landscape of hepatitis infection
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
Phase 3 Treatment-Naïve and Treatment-Experienced
Multimodal Management of Opioid-Induced Constipation
Interactive Workshop.
THE APP THAT ALLOWS EVERY DOCTOR TO PRACTICE:
Chronic HCV Infection and CKD
Edo Agustian Indonesian Drug Users Network
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Volume 65, Issue 5, Pages (November 2016)
Talking to Patients About HCV Treatment
Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Chronic Hepatitis C Virus Infection
Starting Strong: Initial Evaluation of the Patient With HCV
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
HCV: Who Should We Screen and Why?
Volume 68, Issue 5, Pages (May 2018)
Expanding the Universe of Viral Hepatitis Treaters
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
The Patient Journey to Remission in MDD: A Collaborative Approach
HCV Care in Unique Patient Populations
Ask the Onychomycosis Expert, Part 2
The HCV Revolution: Are You and Your Practice Ready?
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
HIV Management: An Update on the Latest EACS Guidelines
Figure 1 Patients cured of HCV infection
Best Practices in Screening and Linkage to Care in Hepatitis C Virus
Ending HCV: How Do We Get There From Here?
More Than Treatment.
HCV Screening.
Evaluation of the Patient With HCV Infection
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Volume 94, Issue 4, Pages (October 2018)
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
Community Advocacy for HCV: Identify, Link to Care, and Treat to Prevent.
HCV Protease Inhibitors in Clinical Practice
Seizures in the Elderly: Treatment and Special Considerations
New Agents, New Regimens, New Strategies
Virological tools to diagnose and monitor hepatitis C virus infection
Care of the Treatment-naive Patient With HCV/HIV Coinfection
Advancing the Treatment of IBD With Biologics
Primary Biliary Cholangitis
When Is Intrathecal Drug Delivery Appropriate?
Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection
Hepatitis C: After the Diagnosis
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.
Current Controversies and Advances in Hepatorenal Syndrome
KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease    Kidney International.
What Does the Future Hold and What Will It Mean for Patients?
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:
Program Goals Overview Is NEDA a Reasonable Target?
When Is Intrathecal Drug Delivery Appropriate?
Removing Barriers in the HCV Cascade of Care
Lesson 3: The HCV Care Continuum
Managing Hepatitis C in Vermont
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Program Overview

Epidemiology of HCV Infection

HCV Genotypes

Treatments for HCV Infection: DAAs

Criteria for Selecting HCV Treatment

Treatments for HCV Infection

Patients With Advanced Liver Disease

Patients With Advanced Liver Disease (cont)

Should HCV Infection Be Treated in All Patients Before a Liver Transplant?

Patients with Advanced Chronic Kidney Disease

Can All Patients With HCV Infection Be Cured?

Screening and Diagnosis

Access to HCV Treatment

Improving Access to Care

Improving Education: HCV in People Who Inject Drugs

Simplification of HCV Therapy

Simplification of HCV Therapy (cont)

Can Subtyping Be Avoided?

Affordability of HCV Therapy

How Can HCV Experts Raise Awareness of HCV?

Summary

Abbreviations